CLASS I Drug recall · Reported 19 Jun 2019 · FDA Enforcement Report

Amikacin Sulfate Injection, USP (250 mg/ml) vial recalled

Heritage Pharmaceuticals is recalling Amikacin Sulfate Injection, USP (250 mg/ml) vial, distributed nationwide in the US. The recall was initiated on 21 May 2019 and the FDA has classified it as Class I.

Check your package

Lot, batch or date codesLot: VEAC025, EXP 10-2019
NDC23155-290
UPC0323155290325, 0323155290318
Quantity recalled14,960 4 mL vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1398-2019
FDA event ID
82918
Recalling firm
Heritage Pharmaceuticals, East Brunswick, NJ
Manufacturer
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Classification
Class I
Status
Terminated
Recall initiated
21 May 2019
FDA classified
19 Jun 2019
Reported
19 Jun 2019
Type
Voluntary: Firm initiated
Customers notified by
Press Release
Reason category
Sterility

Timeline

21 May 2019Recall initiated by company
19 Jun 2019Classified by FDA+29 days
19 Jun 2019Published in enforcement report+0 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

AMIKACIN SULFATE INJECTION, USP, 1 gram/4 mL (250 mg/ml), 4 mL vial, Rx only, Mfd. by: Emcure Pharmaceuticals, Ltd., Hinjawadi, Pune, India Mfd. for: Heritage Pharmaceuticals Inc.. NDC 23155-290-32

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .

Which lots are affected?

Lot: VEAC025, EXP 10-2019

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class I mean?

Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 82918
ReportedClassRecallCompanyReasonWhere
CLASS IProchlorperazine Edisylate Injection, USP 10 mg/ (5mg/mL) Vial recalledProchlorperazine EdisylateHeritage PharmaceuticalsSterilityNationwide

More recalls from Heritage Pharmaceuticals

All 23

Other Amikacin recalls

All 11